# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target fr...
Piper Sandler analyst Biren Amin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and raises the price target fr...
Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raises the price target from $17...
Chardan Capital analyst Daniil Gataulin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $21 price target.
Needham analyst Serge Belanger maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $15 to...
JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and raises the ...
Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular", the "Company"), an integrated biopharmaceutical company commi...